<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Bardelli, Marco</dc:creator>
  <dc:creator>Frontzek, Karl</dc:creator>
  <dc:creator>Simonelli, Luca</dc:creator>
  <dc:creator>Hornemann, Simone</dc:creator>
  <dc:creator>Pedotti, Mattia</dc:creator>
  <dc:creator>Mazzola, Federica</dc:creator>
  <dc:creator>Carta, Manfredi</dc:creator>
  <dc:creator>Eckhardt, Valeria</dc:creator>
  <dc:creator>D’Antuono, Rocco</dc:creator>
  <dc:creator>Virgilio, Tommaso</dc:creator>
  <dc:creator>González, Santiago F.</dc:creator>
  <dc:creator>Aguzzi, Adriano</dc:creator>
  <dc:creator>Varani, Luca</dc:creator>
  <dc:date>2018-10-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Antibodies to the prion protein, PrP, represent a promising therapeutic approach against  prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern.  Here we describe scPOM-bi, a bispecific antibody designed to function as a molecular  prion tweezer. scPOM-bi combines the complementarity-determining regions of the  neurotoxic antibody POM1 and the neuroprotective POM2, which bind the globular  domain (GD) and flexible tail (FT) respectively. We found that scPOM-bi confers  protection to prion-infected organotypic cerebellar slices even when prion pathology is  already conspicuous. Moreover, scPOM-bi prevents the formation of soluble oligomers  that correlate with neurotoxic PrP species. Simultaneous targeting of both GD and FT  was more effective than concomitant treatment with the individual molecules or targeting  the tail alone, possibly by preventing the GD from entering a toxic-prone state. We  conclude that simultaneous binding of the GD and flexible tail of PrP results in strong  protection from prion neurotoxicity and may represent a promising strategy for anti-prion  immunotherapy.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/318891</dc:identifier>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1318891</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/318891/files/Bardelli_PP_2018.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.ppat.1007335</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1318891</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Plos pathogens. - 2018, vol. 14, no. 10, p. e1007335</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
